Indian Journal of Physical Medicine and Rehabilitation

Register      Login

VOLUME 31 , ISSUE 4 ( October-December, 2020 ) > List of Articles


A Review on the Types, Risk Factors, Diagnosis, and Treatment of Cerebral Palsy

Surajit Bhattacharjee

Keywords : Antioxidants, Cerebral palsy, Diagnosis, Paralysis, Therapy

Citation Information : Bhattacharjee S. A Review on the Types, Risk Factors, Diagnosis, and Treatment of Cerebral Palsy. Indian J Phy Med Rehab 2020; 31 (4):96-100.

DOI: 10.5005/jp-journals-10066-0088

License: CC BY-NC 4.0

Published Online: 17-12-2021

Copyright Statement:  Copyright © 2020; The Author(s).


Introduction: Cerebral palsy (CP) is the principal cause of disability in children. It is a neuromuscular disease that occurs due to the lesion in the infant's cerebral motor cortex that is acquired before, at, or within 5 years of birth. Aim and objective: The purpose of this review is to inform the persons who are working on rehabilitation services, doctors, and well-wishers of disabled children to reduce their problems by diagnosing the type of CP and by using suitable bioactive molecules, antioxidants, chemicals, and different therapies. Materials and methods: Eligible articles of various journals which are obtained from the Internet were studied very carefully to establish the results of types, risk factors, diagnosis, and the management of CP. Results: Total 76 reviews or research-based journal articles were reviewed. Among them, 28 were correlated with diagnosis, 7 were related with risk factors, 6 were associated with diagnosis, 20 were linked with the prevention, and the rest 15 articles were connected with the introductory part of CP. Conclusion: The findings of this article emphasize describing the types, risk factors, types, correct diagnosis methods, and treatment processes of CP.

  1. Badawi N, Watson L, Petterson B, et al. What constitutes cerebral palsy? Dev Med Child Neurol 1998;40(8):520–527. DOI: 10.1111/j.1469-8749.1998.tb15410.x.
  2. Hutton JL. Cerebral palsy life expectancy. Clin Perinatol 2006;33(2):545–555. DOI: 10.1016/j.clp.2006.03.016.
  3. Byrne R, Noritz G, Maitre NL, et al. Implementation of early diagnosis and intervention guidelines for cerebral palsy in a high-risk infant follow-up clinic. Pediatr Neurol 2017;76:66–71. DOI: 10.1016/j.pediatrneurol.2017.08.002.
  4. Karen WK. Cerebral palsy: an overview. Am Fam Physician 2006;73:91–100.
  5. Panteliadis C, Panteliadis P, Vassilyadi F. Hallmarks in the history of cerebral palsy: from antiquity to mid-20th century. Brain Develop 2013;35(4):285–292. DOI: 10.1016/j.braindev.2012.05.003.
  6. Camilli A, Jenkner F, Lena G. Contribution to the study of the etiopathogenesis of cerebral palsy in children, by means of analysis of perinatal mortality. Arch Ital Pediatr Pueric 1967;25(1):17–22.
  7. Haak P, Lenski M, Hidecker MJC, et al. Cerebral palsy and aging. Dev Med Child Neurol 2009;4:16–23. DOI: 10.1111/j.1469-8749.2009.03428.x.
  8. Odding E, Roebroeck ME, Stam HJ. The epidemiology of cerebral palsy: incidence, impairments and risk factors. Disabil Rehabil 2006;28(4):183–191. DOI: 10.1080/09638280500158422.
  9. Reddihough DS, Collins KJ. The epidemiology and causes of cerebral palsy. Aust J Physiother 2003;49(1):7–12. DOI: 10.1016/s0004-9514(14)60183-5.
  10. Banerjee TK, Hazra A, Biswas A, et al. Neurological disorders in children and adolescents. Indian J Pediatr 2009;76(2):139–146. DOI: 10.1007/s12098-008-0226-z.
  11. Day SM, Reynolds RJ, Kush SJ. Extrapolating published survival curves to obtain evidence-based estimates of life expectancy in cerebral palsy. Dev Med Child Neurol 2015;57(12):1105–1118. DOI: 10.1111/dmcn.12849.
  12. Liu JM, Li S, Lin Q. Prevalence of cerebral palsy in China. Int J Epidemiol 1999;28(5):949–954. DOI: 10.1093/ije/28.5.949.
  13. Blair E, Watson L. Epidemiology of cerebral palsy. Semin Fetal Neonatal Med 2006;11(2):117–125. DOI: 10.1016/j.siny.2005. 10.010.
  14. Gibson CS, MacLennan AH, Goldwater PN. Antenatal causes of cerebral palsy: associations between inherited thrombophilias, viral and bacterial infection, and inherited susceptibility to infection. Obstet Gynecol Surv 2003;58(3):209–220. DOI: 10.1097/01.OGX.0000055205.21611.6E.
  15. Shankaran S. Prevention, diagnosis, and treatment of cerebral palsy in near-term and term infants. Clin Obstet Gynecol 2008;51(4):829–839. DOI: 10.1097/GRF.0b013e3181870c35.
  16. Sellier E, Platt MJ, Andersen GL, et al. Decreasing prevalence in cerebral palsy: a multi-site European population-based study, 1980 to 2003. Dev Med Child Neurol 2016;58(1):85–92. DOI: 10.1111/dmcn.12865.
  17. Elia AE, Bagella CF, Ferré F, et al. Deep brain stimulation for dystonia due to cerebral palsy: a review. Eur J Paediatr Neurol 2018;22(2):308–315. DOI: 10.1016/j.ejpn.2017.12.002.
  18. Rodríguez-Reyes G, Alessi-Montero A, Díaz-Martínez L, et al. Botulinum toxin, physical and occupational therapy, and neuromuscular electrical stimulation to treat spastic upper limb of children with cerebral palsy: a pilot study. Artif Organs 2010;34(3):230–234. DOI: 10.1111/j.1525-1594.2009.00768.x.
  19. Hemachithra C, Meena N, Ramanathan R, et al. Immediate effect of horse riding simulator on adductor spasticity in children with cerebral palsy: a randomized controlled trial. Physiother Res Int 2020;25(1):e1809. DOI: 10.1002/pri.1809.
  20. Pitcher CA, Elliott CM, Valentine JP, et al. Muscle morphology of the lower leg in ambulant children with spastic cerebral palsy. Muscle Nerve 2018;58(6):818–823. DOI: 10.1002/mus.26293.
  21. Karamitopoulos MS, Nirenstein L. Neuromuscular foot: spastic erebral palsy. Foot Ankle Clin 2015;20(4):657–668. DOI: 10.1016/j.fcl.2015.07.008.
  22. Brunner R. Principles of treatment of spastic palsy in children: a critical review. Orthopade 2014;43(7):643–648. DOI: 10.1007/s00132-013-2218-6.
  23. Jiang H, Li X, Jin C, et al. Early diagnosis of spastic cerebral palsy in infants with periventricular white matter injury using diffusion tensor imaging. AJNR Am J Neuroradiol 2019;40(1):162–168. DOI: 10.3174/ajnr.A5914.
  24. Kaandorp JJ, Benders MJ, Rademaker CM, et al. Antenatal allopurinol for reduction of birth asphyxia induced brain damage (ALLO-Trial); a randomized double blind placebo controlled multicenter study. BMC Pregnancy Childbirth 2010;10(1):1–6. DOI: 10.1186/1471-2393-10-8.
  25. Remijn L, van den Engel-Hoek L, Satink T, et al. “Everyone sees you sitting there struggling with your food”: experiences of adolescents and young adults with cerebral palsy. Disabil Rehabil 2019;41(16):1898–1905. DOI: 10.1080/09638288.2018.1451923.
  26. Mukhopadhyay R, Mahadevappa M, Lenka PK, et al. Correction of toe-walking gait in children with spastic cerebral palsy by using electrical stimulation therapy. Conf Proc IEEE Eng Med Biol Soc 2018. 3529–3532. DOI: 10.1109/EMBC.2018.8513043.
  27. Vaz DV, Cotta Mancini M, Fonseca ST, et al. Muscle stiffness and strength and their relation to hand function in children with hemiplegic cerebral palsy. Dev Med Child Neurol 2006;48(9):728–733. DOI: 10.1017/S0012162206001563.
  28. Hoare BJ, Wallen MA, Thorley MN, et al. Constraint-induced movement therapy in children with unilateral cerebral palsy. Cochrane Database Syst Rev 2019;4:CD004149. DOI: 10.1002/14651858.CD004149.pub3.
  29. Huntsman R, Lemire E, Norton J, et al. The differential diagnosis of spastic diplegia. Arch Dis Child 2015;100(5):500–504. DOI: 10.1136/archdischild-2014-307443.
  30. Givon U. Muscle weakness in cerebral palsy. Acta Orthop Traumatol Turc 2009;43(2):87–93. DOI: 10.3944/AOTT.2009.087.
  31. Pauk J, Ihnatouski M, Daunoraviciene K, et al. Research of the spatial-temporal gait parameters and pressure characteristic in spastic diplegia children. Acta Bioeng Biomech 2016;18(2):121–129.
  32. Ozkan Y. Child's quality of life and mother's burden in spastic cerebral palsy: a topographical classification perspective. J Int Med Res 2018;46(8):3131–3137. DOI: 10.1177/0300060518772758.
  33. Gormley ME, Krach LE, Piccini L. Spasticity management in the child with spastic quadriplegia. Eur J Neuro 2001;5(s5):127–135. DOI: 10.1046/j.1468-1331.2001.00045.x.
  34. Monbaliu E, Himmelmann K, Lin JP, et al. Clinical presentation and management of dyskinetic cerebral palsy. Lancet Neurol 2017;16(9):741–749. DOI: 10.1016/S1474-4422(17)30252-1.
  35. Beckung E, Hagberg G. Correlation between ICIDH handicap code and gross motor function classification system in children with cerebral palsy. Dev Med Child Neurol 2000;42(10):669–673. DOI: 10.1017/s0012162200001237.
  36. Platt MJ, Krageloh-Mann I, Cans C. Surveillance of cerebral palsy in Europe: reference and training manual. Med Educ 2009;43(5):495–496. DOI: 10.1111/j.1365-2923.2009.03351.x.
  37. Monbaliu E, de Cock P, Ortibus E, et al. Clinical patterns of dystonia and choreoathetosis in participants with dyskinetic cerebral palsy. Dev Med Child Neurol 2016;58(2):138–144. DOI: 10.1111/dmcn.12846.
  38. Cheney PD. Pathophysiology of the corticospinal system and basal ganglia in cerebral palsy. Ment Ret and Dev Disa Res Rev 1998;3:153–167.
  39. Manto MU, Pandolfo M. The cerebellum and its disorders. Cambridge: Camb Univ Press; 2002. pp. 97–120.
  40. McHale D, Jackson A, Campbell D, et al. A gene for ataxic cerebral palsy maps to chromosome 9p12-q12. Eur J Hum Genet 2000;8(4):267–272. DOI: 10.1038/sj.ejhg.5200445.
  41. Ingram TTS. Congenital ataxic syndromes in cerebral palsy. Acta Paediatr Scand 1962;51(2):209–221. DOI: 10.1111/j.1651-2227.1962.tb06531.x.
  42. Straub K, Obrzut JE. Effects of cerebral palsy on neurophsyological function. J Dev and Phy Dis 2009;21(2):153–167. DOI: 10.1007/s10882-009-9130-3.
  43. Zhou XJ, Qiu HB, Xu H, et al. Risk factors related to infantile spastic cerebral palsy among 145 cases. Zhonghua Liu Xing Bing Xue Za Zhi 2013;34(4):389–392.
  44. Krageloh-Mann I, Cans C. Cerebral palsy update. Brain and Dev 2009;31(7):537–544. DOI: 10.1016/j.braindev.2009.03.009.
  45. Öztürk A, Demirci F, Yavuz T, et al. Antenatal and delivery risk factors and prevalence of cerebral palsy in Duzce (Turkey). Brain Dev 2007;29(1):39–42. DOI: 10.1016/j.braindev.2006.05.011.
  46. Strijbis EMM, Oudman I, van Essen P, et al. Cerebral palsy and application of the international criteria for acute intrapartum hypoxia. Obstet Gynecol 2006;107(6):1357–1365. DOI: 10.1097/01.AOG.0000220544.21316.80.
  47. Hankins GDV, Speer M. Defining the pathogenesis and pathophysiology of neonatal encephalopathy and cerebral palsy. Obstet Gynecol 2003;102(3):628–636. DOI: 10.1016/s0029-7844(03)00574-x.
  48. MacLennan A. A template for defining a causal relation between acute intrapartum events and cerebral palsy: International consensus statement. BMJ 1999;319(7216):1054–1059. DOI: 10.1136/bmj.319.7216.1054.
  49. Suvanand S, Kapoor SK, Reddaiah VF, et al. Risk factors for cerebral palsy. Indian J Pediatr 1997;64(5):677–685. DOI: 10.1007/BF02726124.
  50. Palmer FB. Strategies for the early diagnosis of cerebral palsy. J Pediatr 2004;145(2 Suppl):S8–S11. DOI: 10.1016/j.jpeds.2004.05.016.
  51. Wu YW, Day SM, Strauss DJ, et al. Prognosis for ambulation in cerebral palsy: a population-based study. Pediatrics 2004;114(5):1264–1271. DOI: 10.1542/peds.2004-0114.
  52. Park N, Lee J, Sung KH, et al. Design and validation of automated femoral bone morphology measurements in cerebral palsy. J Digit Imaging 2014;27(2):262–269. DOI: 10.1007/s10278-013-9643-2.
  53. Choi JY, Choi YS, Rha D, et al. The clinical outcomes of deep gray matter injury in children with cerebral palsy in relation with brain magnetic resonance imaging. Res Dev Disabil 2016;55:218–225. DOI: 10.1016/j.ridd.2016.04.010.
  54. Padfield N, Zabalza J, Zhao H, et al. EEG-based brain-computer lnterfaces using motor-imagery: techniques and challenges. Sensors (Basel) 2019;19:1423.
  55. Lee RW, Poretti A, Cohen JS, et al. A diagnostic approach for cerebral palsy in the genomic era. Neuromolecular Med 2014;16(4):821–844. DOI: 10.1007/s12017-014-8331-9.
  56. O'Shea TM. Diagnosis, treatment, and prevention of cerebral palsy. Clin Obstet Gynecol 2000;51(4):816–828. DOI: 10.1097/GRF.0b013e3181870ba7.
  57. O'Shea TM. Diagnosis, treatment, and prevention of cerebral palsy. Clin Obstet Gynecol 2008;51(4):816–828. DOI: 10.1097/GRF.0b013e3181870ba7.
  58. Ji H, Tan S, Igarashi J, et al. Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy. Ann Neurol 2009;65(2):209–217. DOI: 10.1002/ana.21555.
  59. Lekic T, Manaenko A, Rolland W, et al. Neuroprotection by melatonin after germinal matrix hemorrhage in neonatal rats. Acta Neurochir Suppl 2011;111:201–206. DOI: 10.1007/978-3-7091-0693-8_34.
  60. Lekic T, Manaenko A, Rolland W, et al. Protective effect of hydrogen gas therapy after germinal matrix hemorrhage in neonatal rats. Acta Neurochir Suppl 2011;111:237–241. DOI: 10.1007/978-3-7091-0693-8_40.
  61. Conde-Agudelo A, Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants <34 weeks’ gestation: a systematic review and metaanalysis. Am J Obstet Gynecol 2009;200(6):595–609. DOI: 10.1016/j.ajog.2009.04.005.
  62. Haynes RL, Baud O, Li J, et al. Oxidative and nitrative injury in periventricular leukomalacia: a review. Brain Pathol 2005;15(3):225–233. DOI: 10.1111/j.1750-3639.2005.tb00525.x.
  63. Gressens P, Schwendimann L, Husson I, et al. Agomelatine, a melatonin receptor agonist with 5-HT(2C) receptor antagonist properties, protects the developing murine white matter against excitotoxicity. Eur J Pharmacol 2008;588(1):58–63. DOI: 10.1016/j.ejphar.2008.04.016.
  64. Girard S, Sébire H, Brochu ME, et al. Postnatal administration of IL-1Ra exerts neuroprotective effects following perinatal inflammation and/or hypoxic-ischemic injuries. Brain Behav Immun 2012;26(8):1331–1339. DOI: 10.1016/j.bbi.2012.09.001.
  65. Wei X, Du Z, Zhao L, et al. IFATS collection: The conditioned media of adipose stromal cells protect against hypoxia-ischemia-induced brain damage in neonatal rats. Stem Cells 2009;27(2):478–488. DOI: 10.1634/stemcells.2008-0333.
  66. Fantacci C, Capozzi D, Ferrara P, et al. Neuroprotective role of nerve growth factor in hypoxic-ischemic brain injury. Brain Sci 2013;3(4):1013–1022. DOI: 10.3390/brainsci3031013.
  67. Harvey AR, Baker LB, Reddihough DS, et al. Trihexyphenidyl for dystonia in cerebral palsy. Syst Rev 2018;5:CD012430. DOI: 10.1002/14651858.CD012430.pub2.
  68. Li Q, Li H, Roughton K, et al. Lithium reduces apoptosis and autophagy after neonatal hypoxia–ischemia. Cell Death Dis 2010;1(7):e56. DOI: 10.1038/cddis.2010.33.
  69. Koldoff EA, Holtzclaw BJ. Physical activity among adolescents with cerebral palsy: an integrative review. J Pediatr Nurs 2015;30(5):e105–117. DOI: 10.1016/j.pedn.2015.05.027.
  70. Dias BLS, Fernandes AR, Filho MHS. Treatment of drooling with sublingual atropine sulfate in children and adolescents with cerebral palsy. Arq Neuropsiquiatr 2017;75(5):282–287. DOI: 10.1590/0004-282x20170033.
  71. Garcia SSF, Gomez GMT, Guzman PJE. Toxina botulinica A y terapia fisica, en la marcha en parilisis cerebral botulinum toxin A and physical therapy in gait in cerebral palsy. Rev Med Inst Mex Seguro Soc 2017;55:18–24.
  72. Gonnade N, Lokhande V, Ajij M, et al. Phenol versus botulinum toxin a injection in ambulatory cerebral palsy spastic diplegia: a comparative study. J Pediatr Neurosci 2017;12(4):338–343. DOI: 10.4103/jpn.JPN_123_17.
  73. Hsieh YL, Yang CC, Sun SH, et al. Effects of hippotherapy on body functions, activities and participation in children with cerebral palsy based on ICF-CY assessments. Disabil Rehabil 2017;39(17):1703–1713. DOI: 10.1080/09638288.2016.1207108.
  74. Tekin F, Kavlak E, Cavlak U, et al. Effectiveness of neuro-developmental treatment (bobath concept) on postural control and balance in cerebral palsied children. J Back Musculoskelet Rehabil 2018;31(2):397–403. DOI: 10.3233/BMR-170813.
  75. Aboutorabi A, Arazpour M, Ahmadi Bani M, et al. Efficacy of ankle foot orthoses types on walking in children with cerebral palsy: a systematic review. Ann Phys Rehabil Med 2017;60(6):393–402. DOI: 10.1016/
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.